Goals and documentation of quality decision-making practices

Slides:



Advertisements
Similar presentations
Ron Bass, J.D., AICP, Senior Regulatory Specialist Jones & Stokes Common NEPA Mistakes and How to Avoid Them January 17, 2008 Oregon Department of Transportation.
Advertisements

TM/WSP 5-9 Nov Group A1- National position - Stakeholders involvement - Legislative framework - Safeguards QUESTIONS / DIFFICULTIES Can nuclear.
Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward Francois Dionne- Centre for Clinical Epidemiology.
Presentation By: Chris Wade, P Eng. Finally … a best practice for selecting an engineering firm.
1 Module 1 INTRODUCTION TO DECISION ANALYSIS. 2 Introduction To Decision Analysis Learning Objectives Reasons for studying decision analysis Basic sources.
Lesson plan for FND2610 “Polartec case” day 1.Case discussion: business decisions and ethical issues elucidated 2.A framework for ethical decision- making.
Elements of an Automotive Products NTBs Initiative United States Perspective.
Country Summary for Ukraine (part 1) status for Roman Volosyanchuk, IUCN CPC.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Subcommittee on Design New Strategies for Cost Estimating Research on Cost Estimating and Management NCHRP Project 8-49 Annual Meeting Orlando, Florida.
Chapter 3 Marketing Decision Making and Case Analysis.
Group 2 Comments IRPA 2 nd International Workshop Radiation Protection Culture Charleston, SC February 10-11, 2011.
Division of Technology, Industry, and Economics Economics and Trade Branch SESSION 7 - How to do Integrated Assessment Stage D: Issuing policy recommendations.
Introducing Regulatory Impact Analysis into the Turkish Legal Framework Improving Transparency, Consultation and Communication of RIAs March 2009.
Organizations of all types and sizes face a range of risks that can affect the achievement of their objectives. Organization's activities Strategic initiatives.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
Overview MRD Enterprise MRD Process
Presentation Why M&E Hanoi, 03 June 2014
Technical Business Consultancy Project
An Overview on Risk Management
MEP Interest Group on Brain, Mind and Pain
Moderator: Laura Foose
EIA approval process, Management plan and Monitoring
Enbridge Presentation to the NEB Modernization Expert Panel Edmonton, AB – Mar 7, 2017.
MOSH Adoption Team Training
Regulatory agency and pharmaceutical company responses mapped to the 10 Quality Decision Making Practices (n=76) Legend Best practice Needs improvement.
A PF Solutions Presentation
Data Architecture World Class Operations - Impact Workshop.
Patient Involvement in the HTA Decision Making Process
FDA Transparency Initiative and
Student Engagement: the QAA Experience
HEALTH IN POLICIES TRAINING
Public Participation for Executives and Decision Makers
Active Communities The Scottish Government has defined physical activity as one of the six priorities for Community Planning Partnership (CPP) Single Outcome.
The Quality of an Emission Inventory
Transforming Grading Robert Marzano
Presentation template
Qualification Standard (QS) – Status Purposes and Uses
Successful Bid Writing:
ACTION RESEARCH.
Ten Quality Decision-Making Practices for organisational decision making for pharmaceutical company leadership team and sub-teams In order for organisations.
Communication and Consultation with Interested Parties by the RB
Vision, Mission, and Goals
Module 2 Key Principles of the Peer Review Programme
Scientific competence Communication and transparency
Participative Process Reviews
THE independent evaluation office of Undp Independence, credibility and use IPDET, 30 June 2014 Indran A. Naidoo Director.
Regulatory Responses (n=11) Company Responses (n=20)
Building quality in HTA process and decision making
Proposed activities. Proposed activities Activity 1: Situation review First step Review of insurance market in Peru: Identify the main elements of.
ROOTS 1+2 Advocacy toolkit
TEMPLATE FOR PLANNING A DISCUSSION
Regulatory Responses (n=11) Company Responses (n=20)
Building a Sustainable Community Collaboration
The slide shows the seven key steps that make up a systematic approach to benefit-risk assessment for medicines. Source: The CIRS Benefit-Risk Research.
Commission strategy to
Engineering Processes
Curriculum & Instruction
Guiding Principles of Engagement Outline
Assessment of quality decision making in regulatory agencies and pharmaceutical companies with QoDoS (Quality of Decision Making Orientation Scheme) Not.
Presentation by Bill Pauley European Division DFP
5.0 Management Responsibility
Code of Ethics for CDM Professionals
Enablers of an effective regulatory review
A Simple Template for Strategy
The UMBRA Eight-Step Benefit-Risk Framework
Resourcing Consumer Engagement
Code of Ethics for CDM Professionals
2019 CIRS survey: Methodologies to improve decision-making documentation during medicines development and review – gap analysis Do you think your current.
Enhancing Learning in Practice
Presentation transcript:

Goals and documentation of quality decision-making practices From Walker S et al. Quality decision-making practices. Available at www.cirsci.org/wp-content/uploads/2018/01/CIRS-Book-Quality-Decision-Making-Practices.pdf Ten Quality Decision-Making Practices (QDMPs) have been identified, based on semi-structured interviews with 29 key opinion leaders from pharmaceutical companies and regulatory agencies.1 Participants at the June 2017 CIRS Workshop reorganised these ten practices, grouping them as those that establish who, why and how decisions are made (Practices 1,2 and 3), those that ensure decision quality, relevance and importance (Practices 4, 6 and 7), those that consider decision alternatives and impact (Practices 5 and 8) and those that involve decision transparency and communication (Practices 9 and 10). Participants further agreed that documentation is a key marker of quality decision making and specified that documentation for practices 1, 2 and 3 should include documentation of the decision-making framework and weighting criteria and the decision-making standard operating procedures (SOPs), including a rigorous documentation of the roles and responsibilities of decision makers. These decision makers should be accountable for adherence to the SOPs and decisions should reflect their perspectives. Documentation of practise 4, 6 and 7 should include documentation of the framework used for evaluating biases, uncertainties that were considered and fully defined triggers for the re-evaluation of the decision. Documentation for practices 5 and 8 should include documentation of the alternatives to the decision that were considered and the template that was used to perform an analysis of the impact of the decision. Finally, documentation for practices 9 and 10 should include a template to be used for the communication of the decision. Donelan R et al. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives. Pharmacoepidemiol Drug Safety. 2015;24:319-328. From Walker S et al. “Quality decision-making practices.” Netherlands: Off Page, 2017. Available at www.cirsci.org/wp-content/uploads/2018/01/CIRS-Book-Quality-Decision-Making-Practices.pdf